Clinical Trial Update: Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) [Phase 3]

View source ↗

Summary

Phase 3 trial of pexidartinib in pigmented villonodular synovitis and related tenosynovial giant cell tumors completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumors of the Tendon Sheath
• Pigmented Villonodular Synovitis
• Tenosynovial Giant Cell Tumor

Drugs mentioned

• Pexidartinib (pexidartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath | Phase 3 | Status: COMPLETED | Results posted: 2020-01-10